Study S002419

Separate and Combined Extrapancreatic Effects of Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06895408
Acronym: GA-19b
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: COMPLETED
Enrollment: 12
Start: 2025-02-19
Primary completion: 2025-07-14
Lead sponsor: University Hospital, Gentofte, Copenhagen
Conditions: Pancreatectomy; Hyperglycemia
Interventions: OTHER:Intravenous Infusion
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Plasma glucose [Up to two months]
Plasma glucagon [Up to two months]
Plasma Insulin/C-peptide [Up to two months]
Plasma triglycerides [Up to two months]
Plasma CTX [Up to two months]
Plasma PINP [Up to two months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011917	Acute GIP and GLP-1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals. Krogh LSL, Diabetes, obesity & metabolism	2026	Randomized trial	PMID 42225304 DOI	cites ClinicalTrials.gov:NCT06895408; registry reference DERIVED:42225304